Harvard University Genomic Medicines Fund
Supports cutting-edge research at Harvard on genome editing and genomic medicine, from discovery to clinical application, to advance prevention or treatment of human disease.
Funder: Harvard University
Due Dates (Anticipated): March 2027: Full application submission to OVPR | March 2027: Sponsor/online application deadline
Funding Amounts: Up to $200,000 per year for 2 years (max $400,000 direct costs); one-time, no-cost extension possible
Summary: Supports research at Harvard advancing genome editing and genomic medicine, from discovery to clinical application, for the prevention or treatment of human disease.
Key Information: Proposals are subject to Editas Genomics’ first right to negotiate a license for resulting inventions.
Description
The Harvard University Genomic Medicines Fund provides internal funding to support cutting-edge research in genome editing and genomic medicine at Harvard University. The fund is intended to catalyze projects that are useful or relevant to the prevention or treatment of human disease, spanning the full spectrum from discovery-oriented or exploratory studies, to research addressing the translational gap between discovery and clinical application, and projects nearing clinical implementation and commercialization. The program is administered by the Office of the Vice Provost for Research (OVPR).
